Shares of Forte Biosciences, Inc. (FBRX) fell more than 80 percent as the company reported on Thursday that the topline data from its phase 2 trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint. Based on the data, the company said it will not continue to advance FB-401.
FB-401 was the lead product of this clinical-stage biopharmaceutical company focused on dermatology. The company started the multi-center, placebo-controlled clinical trial of FB-401 in September 2020.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com